The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 20, 2010
Filed:
Feb. 13, 2007
Kevin D. Mccormick, Basking Ridge, NJ (US);
Christopher W. Boyce, Flemington, NJ (US);
Neng-yang Shih, Warren, NJ (US);
Chia-yu Huang, Princeton Junction, NJ (US);
Robert G. Aslanian, Rockaway, NJ (US);
Salem Fevrier, Cranford, NJ (US);
BO Liang, Lawrenceville, NJ (US);
Rong-qiang Liu, Kendall Park, NJ (US);
Ruiyan Liu, Yardley, PA (US);
Pietro Mangiaracina, Monsey, NY (US);
Manuel DE Lera Ruiz, Branchburg, NJ (US);
Younong Yu, East Brunswick, NJ (US);
Lisa Guise-zawacki, Yardley, PA (US);
Junying Zheng, Bridgewater, NJ (US);
Kevin D. McCormick, Basking Ridge, NJ (US);
Christopher W. Boyce, Flemington, NJ (US);
Neng-Yang Shih, Warren, NJ (US);
Chia-Yu Huang, Princeton Junction, NJ (US);
Robert G. Aslanian, Rockaway, NJ (US);
Salem Fevrier, Cranford, NJ (US);
Bo Liang, Lawrenceville, NJ (US);
Rong-qiang Liu, Kendall Park, NJ (US);
Ruiyan Liu, Yardley, PA (US);
Pietro Mangiaracina, Monsey, NY (US);
Manuel de Lera Ruiz, Branchburg, NJ (US);
Younong Yu, East Brunswick, NJ (US);
Lisa Guise-Zawacki, Yardley, PA (US);
Junying Zheng, Bridgewater, NJ (US);
Schering Corporation, Kenilworth, NJ (US);
Abstract
In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.